Epizyme Wins Orphan Drug Status - Analyst Blog

By
A A A

Recently, Epizyme, Inc. ( EPZM ) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to the company's pipeline candidate EPZ-5676. Epizyme is developing the candidate for treating a rare form of acute leukemia characterized by a re-arranged MML gene (mixed lineage leukemia). The re-arrangement is caused by chromosomal translocation. Epizyme is currently in phase I studies.

We note that the FDA grants orphan drug designation to those drugs that are meant for treating rare diseases affecting not more than 200,000 people in the U.S. The orphan drug designation granted to EPZ-5676 will facilitate its development by providing incentives such as tax credits and research and development grant funding.

We note that Epizyme has the entire rights pertaining to EPZ-5676 in the U.S. The company granted Celgene Corporation ( CELG ) an exclusive license to develop and commercialize the candidate in ex-U.S. markets. Moreover, in Apr 2013, Epizyme joined forces with Abbott Laboratories ( ABT ) for the development of a molecular companion diagnostic test for use with EPZ-5676.

Under this deal, Abbott Labs will use its fluorescence in situ hybridization technology to develop the test. It will help in identifying patients eligible for treatment with EPZ-5676. Financial details of the deal were not provided.

Epizyme was also in the news recently when it raised $88.7 million (gross) through an initial public offering. The funds will help Epizyme in developing its pipeline further.

Epizyme, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). Gilead Sciences, Inc. ( GILD ) looks well-positioned in the biopharma space with a Zacks Rank #1 (Strong Buy).



ABBOTT LABS (ABT): Free Stock Analysis Report

CELGENE CORP (CELG): Free Stock Analysis Report

EPIZYME INC (EPZM): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ABT , CELG , EPZM , GILD

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com